Alkylsilyl speciation and direct sample preparation of plant cannabinoids prior to their analysis by GC-MS

作者: Blanka Fodor , Imre Boldizsár , Ibolya Molnár-Perl

DOI: 10.1016/J.ACA.2018.03.049

关键词:

摘要: Abstract A literature criticism is given on methods currently using gas chromatography mass spectrometry (GC-MS) to determine plant cannabinoids (p-CBDs). In this study, trialkylsilylation of seven p-CBDs (including their transformation products formed in the drug user's body) was compared applying various alkylsilyl reagents 1 and fragmentation properties corresponding derivatives were characterized. Derivatization, quantitation related model investigations optimized as a function reaction times conditions. Special emphasis put (i) maximum responses species, (ii) proportions stable products, suitable for selective all simultaneously. Results, novel field confirmed that HMDS + TFA, never applied reagent before, serves derivatization choice. These species characterized by retention, analytical performance characteristics. solutions with injected amounts range 20 pg–2000 pg, repeatability (average 4.98% RSD, varying between 2.98 6.2% RSD), linearity (R2, 0.9956–0.9995), LOQ (20–80 pg/μL species) recovery (95.2–104%) values defined. The practical utility proposal, along method development validation, shown particularly unique manner supported novel, extraction free, direct sample preparation working strategy. For purpose, two Cannabis-type ruderalis (C-trd) tissues (C-trd1, C-trd2) directly derivatized presence matrix. This process, which approaches green chemistry, performed without use organic solvents, associated self p-CBD contents C-trd tissues. Applying 0.5–2.0 mg dried tissues, adding standards, following confirmed: C-trd1 6.6 μg/mg CBD, 4.4 μg/mg CBN 1.3 μg/mg CBC, while C-trd2 0.46 μg/mg 0.27 μg/mg CBC 0.19 μg/mg CBG found. latter results (2.52–4.99% 0.9640–0.9997) (87.9–109%) data.

参考文章(42)
E Hidvégi, G P Somogyi, Detection of cannabigerol and its presumptive metabolite in human urine after Cannabis consumption. Die Pharmazie. ,vol. 65, pp. 408- 411 ,(2010)
Cristiana Gambelunghe, Riccardo Rossi, Chiara Ferranti, Ruggero Rossi, Mauro Bacci, Hair analysis by GC/MS/MS to verify abuse of drugs. Journal of Applied Toxicology. ,vol. 25, pp. 205- 211 ,(2005) , 10.1002/JAT.1054
Ju-Yeon Moon, Jin Young Kim, Myeong Hee Moon, Bong Chul Chung, Moon Kyo In, Man Ho Choi, Validated gas chromatographic–mass spectrometric analysis of urinary cannabinoids purified with a calcium-hardened β-cyclodextrin polymer Journal of Chromatography A. ,vol. 1204, pp. 87- 92 ,(2008) , 10.1016/J.CHROMA.2008.07.083
J. L. Villamor, A. M. Bermejo, M. J. Tabernero, P. Fernández, Determination of Cannabinoids in Human Hair by GC/MS Analytical Letters. ,vol. 37, pp. 517- 528 ,(2004) , 10.1081/AL-120028624
Inés Racamonde, Eugenia Villaverde-de-Sáa, Rosario Rodil, José Benito Quintana, Rafael Cela, Determination of Δ9-tetrahydrocannabinol and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in water samples by solid-phase microextraction with on-fiber derivatization and gas chromatography-mass spectrometry. Journal of Chromatography A. ,vol. 1245, pp. 167- 174 ,(2012) , 10.1016/J.CHROMA.2012.05.017
Janne Martti Mannila, Tomi Jarvinen, M Lehtonen, Pekka Jarho, Determination of Δ9-tetrahydrocannabinol from rabbit plasma by gas chromatography–mass spectrometry using two ionization techniques Journal of Chromatography B. ,vol. 810, pp. 283- 290 ,(2004) , 10.1016/J.JCHROMB.2004.08.014
Ioannis Papoutsis, Panagiota Nikolaou, Artemisia Dona, Constantinos Pistos, Maria Stefanidou, Chara Spiliopoulou, Sotirios Athanaselis, A validated GC–MS method for the determination of Δ9-tetrahydrocannabinol and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in bile samples Forensic Toxicology. ,vol. 30, pp. 51- 58 ,(2012) , 10.1007/S11419-011-0126-1
Robert S. Goodwin, Richard A. Gustafson, Allan Barnes, Wesenyalsh Nebro, Eric T. Moolchan, Marilyn A. Huestis, Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Therapeutic Drug Monitoring. ,vol. 28, pp. 545- 551 ,(2006) , 10.1097/00007691-200608000-00010